Your browser doesn't support javascript.
loading
Follistatin-controlled activin-HNF4α-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
Lin, Tao; Wang, Shanshan; Munker, Stefan; Jung, Kyounghwa; Macías-Rodríguez, Ricardo U; Ruiz-Margáin, Astrid; Schierwagen, Robert; Liu, Hui; Shao, Chen; Fan, Chunlei; Feng, Rilu; Yuan, Xiaodong; Wang, Sai; Wandrer, Franziska; Meyer, Christoph; Wimmer, Ralf; Liebe, Roman; Kroll, Jens; Zhang, Long; Schiergens, Tobias; Ten Dijke, Peter; Teufel, Andreas; Marx, Alexander; Mertens, Peter R; Wang, Hua; Ebert, Matthias P A; Bantel, Heike; N De Toni, Enrico; Trebicka, Jonel; Dooley, Steven; Shin, Donghun; Ding, Huiguo; Weng, Hong-Lei.
Afiliación
  • Lin T; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Wang S; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Munker S; Beijing Institute of HepatologyBeijing You'an HospitalCapital Medical UniversityBeijingChina.
  • Jung K; Department of Medicine IIUniversity Hospital, Campus Großhadern, LMU MunichMunichGermany.
  • Macías-Rodríguez RU; Department of Developmental BiologyMcGowan Institute for Regenerative MedicineUniversity of PittsburghPittsburghPennsylvaniaUSA.
  • Ruiz-Margáin A; Department of GastroenterologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico cityMexico.
  • Schierwagen R; Department of GastroenterologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico cityMexico.
  • Liu H; Translational Hepatology, Medical Department IFrankfurt University HospitalFrankfurtGermany.
  • Shao C; Department of PathologyBeijing You'an HospitalAffiliated with Capital Medical UniversityBeijingChina.
  • Fan C; Department of PathologyBeijing You'an HospitalAffiliated with Capital Medical UniversityBeijingChina.
  • Feng R; Department of Gastroenterology and HepatologyBeijing You'an HospitalAffiliated with Capital Medical UniversityBeijingChina.
  • Yuan X; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Wang S; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Wandrer F; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Meyer C; Department of Gastroenterology, Hepatology and EndocrinologyHannover Medical SchoolHannoverGermany.
  • Wimmer R; Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Liebe R; Department of Medicine IIUniversity Hospital, Campus Großhadern, LMU MunichMunichGermany.
  • Kroll J; Clinic of Gastroenterology, Hepatology and Infectious DiseasesHeinrich Heine UniversityDüsseldorfGermany.
  • Zhang L; Department of Medicine IISaarland University Medical CenterSaarland UniversityHomburgGermany.
  • Schiergens T; Vascular Biology and Tumor AngiogenesisEuropean Center for AngioscienceMedical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Ten Dijke P; Life Sciences Institute and Innovation Center for Cell Signaling NetworkHangzhouChina.
  • Teufel A; Department of General, Visceral, Transplantation, Vascular and Thoracic SurgeryUniversity HospitalLMU MunichMunichGermany.
  • Marx A; Oncode Institute and Department of Cell and Chemical BiologyLeiden University Medical CenterLeidenThe Netherlands.
  • Mertens PR; Division of Hepatology, Division of Clinical Bioinformatics, Department of Medicine II, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Wang H; Clinical Cooperation Unit Healthy MetabolismCenter for Preventive Medicine and Digital Health Baden-WürttembergMedical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Ebert MPA; Institute of PathologyUniversity Medical Center MannheimHeidelberg UniversityMannheimGermany.
  • Bantel H; Clinic of Nephrology and Hypertension, Diabetes and EndocrinologyOtto-von-Guericke-UniversityMagdeburgGermany.
  • N De Toni E; Department of Oncologythe First Affiliated Hospital of Anhui Medical UniversityHefeiChina.
  • Trebicka J; Inflammation and Immune Mediated Disease Laboratory of Anhui ProvinceHefeiChina.
  • Dooley S; Mannheim Institute for Innate ImmunoscienceMannheimGermany.
  • Shin D; Clinical Cooperation Unit Healthy MetabolismCenter of Preventive Medicine and Digital HealthMedical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Ding H; Department of Medicine II, University Medical Center Mannheim, Medical Faculty MannheimHeidelberg UniversityMannheimGermany.
  • Weng HL; Department of Gastroenterology, Hepatology and EndocrinologyHannover Medical SchoolHannoverGermany.
Hepatology ; 75(2): 322-337, 2022 02.
Article en En | MEDLINE | ID: mdl-34435364
ABSTRACT
BACKGROUND AND

AIMS:

In patients with acute liver failure (ALF) who suffer from massive hepatocyte loss, liver progenitor cells (LPCs) take over key hepatocyte functions, which ultimately determines survival. This study investigated how the expression of hepatocyte nuclear factor 4α (HNF4α), its regulators, and targets in LPCs determines clinical outcome of patients with ALF. APPROACH AND

RESULTS:

Clinicopathological associations were scrutinized in 19 patients with ALF (9 recovered and 10 receiving liver transplantation). Regulatory mechanisms between follistatin, activin, HNF4α, and coagulation factor expression in LPC were investigated in vitro and in metronidazole-treated zebrafish. A prospective clinical study followed up 186 patients with cirrhosis for 80 months to observe the relevance of follistatin levels in prevalence and mortality of acute-on-chronic liver failure. Recovered patients with ALF robustly express HNF4α in either LPCs or remaining hepatocytes. As in hepatocytes, HNF4α controls the expression of coagulation factors by binding to their promoters in LPC. HNF4α expression in LPCs requires the forkhead box protein H1-Sma and Mad homolog 2/3/4 transcription factor complex, which is promoted by the TGF-ß superfamily member activin. Activin signaling in LPCs is negatively regulated by follistatin, a hepatocyte-derived hormone controlled by insulin and glucagon. In contrast to patients requiring liver transplantation, recovered patients demonstrate a normal activin/follistatin ratio, robust abundance of the activin effectors phosphorylated Sma and Mad homolog 2 and HNF4α in LPCs, leading to significantly improved coagulation function. A follow-up study indicated that serum follistatin levels could predict the incidence and mortality of acute-on-chronic liver failure.

CONCLUSIONS:

These results highlight a crucial role of the follistatin-controlled activin-HNF4α-coagulation axis in determining the clinical outcome of massive hepatocyte loss-induced ALF. The effects of insulin and glucagon on follistatin suggest a key role of the systemic metabolic state in ALF.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fallo Hepático Agudo / Activinas / Folistatina / Factor Nuclear 4 del Hepatocito Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fallo Hepático Agudo / Activinas / Folistatina / Factor Nuclear 4 del Hepatocito Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article